About Clarivate JCR-based Journal Impact Factors 2025
The Journal Impact Factor is a journal-level bibliometric indicator published by Clarivate in Journal Citation Reports (JCR). It is often abbreviated as JIF; JIF is not a separate impact factor, but simply the abbreviation for Journal Impact Factor.
The 2025 Journal Impact Factor provides a journal-level indication of citation activity. It should be interpreted within the journal’s subject area and together with other information, rather than used as a stand-alone judgment of research quality.
On this website, you can explore Journal Impact Factor records presented as Clarivate JCR-based data, together with the five-year Impact Factor, JCR quartile (Q1–Q4), JCR category rank, publisher details and journal identifiers. Verify important submission or evaluation decisions in the official Clarivate Journal Citation Reports.
Explore by research area
Browse journals by subject
Start with a broad research area, then narrow the list to a specialty or subsubject. These internal subject groups are provided for discovery and are kept separate from official Journal Citation Reports categories.
Popular specialties
Explore medical journal specialties
Browse focused journal lists within Medicine, including citation metrics, quartiles, publishers and identifiers.
Browse journal metrics
Showing records 2,331–2,340 of 20,480
| Rank | Journal | ISSN / eISSN | JCR Impact Factor | 5-Year Impact Factor | JCR Quartile | JCR Category Rank | Publisher |
|---|---|---|---|---|---|---|---|
| 2,261 |
Matter and Radiation at Extremes MATTER RADIAT EXTREM |
2468-2047 2468-080X |
4.700 | 4.700 | Q1 | 22/114 | AIP Publishing |
| 2,261 |
mBio MBIO |
N/A 2150-7511 |
4.700 | 5.500 | Q1 | 33/163 | AMER SOC MICROBIOLOGY |
| 2,261 |
Microporous and Mesoporous Materials MICROPOR MESOPOR MAT |
1387-1811 1873-3093 |
4.700 | 4.800 | Q2 | 19/75 | ELSEVIER |
| 2,261 |
MOLECULAR CANCER RESEARCH MOL CANCER RES |
1541-7786 1557-3125 |
4.700 | 4.900 | Q1 | 77/326 | AMER ASSOC CANCER RESEARCH |
| 2,261 |
Molecular Therapy Methods & Clinical Development MOL THER METH CLIN D |
N/A 2329-0501 |
4.700 | 5.000 | Q2 | 49/195 | CELL PRESS |
| 2,261 |
Nano Communication Networks NANO COMMUN NETW |
1878-7789 1878-7797 |
4.700 | 3.600 | Q2 | 93/366 | ELSEVIER |
| 2,261 |
NATURAL HAZARDS AND EARTH SYSTEM SCIENCES NAT HAZARD EARTH SYS |
1561-8633 1684-9981 |
4.700 | 4.800 | Q1 | 30/258 | COPERNICUS GESELLSCHAFT MBH |
| 2,261 |
Non-coding RNA Research NON-CODING RNA RES |
2468-2160 2468-0540 |
4.700 | 4.400 | Q1 | 78/319 | KEAI PUBLISHING LTD |
| 2,261 |
npj Primary Care Respiratory Medicine NPJ PRIM CARE RESP M |
N/A 2055-1010 |
4.700 | 3.600 | Q1 | 28-Mar | NATURE PORTFOLIO |
| 2,261 |
Nucleic Acid Therapeutics NUCLEIC ACID THER |
2159-3337 2159-3345 |
4.700 | 3.800 | Q1 | 78/319 | MARY ANN LIEBERT, INC |